Loading
A year of nivolumab after chemoradiotherapy and surgery doubled disease-free survival in patients with oesophageal or junctional cancer who still had residual tumour at surgery, the first adjuvant therapy to work in this setting.
Phase 3 placebo-controlled trial of 794 patients with resected stage II to III oesophageal or gastro-oesophageal junction cancer (both histologies) and residual pathological disease after neoadjuvant chemoradiotherapy, randomised 2:1 to nivolumab or placebo for up to one year.
Median disease-free survival was 22.4 versus 11.0 months (hazard ratio 0.69), with benefit in both squamous and adenocarcinoma and regardless of PD-L1 expression; grade 3 to 4 treatment-related adverse events were 13 versus 6 percent.
Adjuvant nivolumab is standard for patients with residual disease after trimodality therapy for oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Nivolumab, New England Journal of Medicine.
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine.
Shares CheckMate 577, Nivolumab.
Shares CheckMate 577, Nivolumab.